Primary Prevention of Cardiovascular Disease

Cardiology (Switzerland)

Volumn 88, Issue , 1997, Pages 32-37

  Mancia, Giuseppe ^a   Carugo, Stefano ^a   Grassi, Guido ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Antihypertensive treatment; Calcium antagonists; Cardiovascular morbidity; Cardiovascular mortality; Clinical trials; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; NIFEDIPINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030830498     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177504     Document Type: Article

References (35)

1. Mancia G, Grassi G: Considerations on current and future trials in hypertension. Blood Press 1996:5:327-332.
2. Kincaid-Smith P, McMichael J, Murphy EA: The clinical course and pathology of hypertension with papilloedema (malignant hypertension). QJ Med 1958;27:117-153.
3. Ruilope LM. Alcazar JM. Rodicio JC: Renal consequences of arterial hypertension. J Hy-pertens 1992:10(suppl 7):s85-s95.
4. National High Blood Pressure Education Program: National High Blood Pressure Education Program Working Group Report on hypertension and chronic renal failure. Arch Intern Med 1991;151:1280-1287.
5. Kashgarian M: Hypertensive disease and kidney structure: in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology. Diagnosis and Management. New York. Raven. 1990, pp 389-398.
6. Wcidman P: Antihypertensive therapy in diabetic patients. J Cardiovasc Pharmacol 1996: 28(suppl 4):S29-S33.
7. Maschio G. Alberti D, Janin G, Locatclli F, Mann JFE. Motolese M. et al: Effect of angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-945.
8. Mancia G: The dilemma of benign nephrosclerosis: The hypcrtensiologists's view. Am J Kid-ney Dis 1991;21 (suppl 2):84-86.
9. Collins R. MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994:50:272-298.
10. Hypertension, Detection and Follow-Up Program Cooperative Group: Five-year findings of the Hypertension, Detection and Follow-Up Program. I. Reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-2571.
11. Lievre M, Leizorovicz A: Treatment of high blood pressure in patients aged over 60 years: Lessons from randomized clinical trials. Cardiol Elderly 1995;3:217-222.
12. Amery A. Birkenhäger W. Brixko P. Bulpitt C. Clement D. Deruytterc M, et al: Mortality and morbidity results from the European Working Party on High blood pressure in the elderly trial. Lancet 1985;i: 1349-1354.
13. Isles CG, Walker LM, Beevers GD, Brown I. Cameron HL, Clarke J, et al: Mortality of patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986;4:141-156.
14. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
15. Weidman P. Ferner C. Saxenhofer H. Vehlin-gcr DE, Trost BN: Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988;35(suppl 6): 118-134.
16. Brown MJ. Castaigne A. Ruilope LM. Mancia G. Rosenthal T. De Leeuw PW. et al: INSIGHT: International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. J Hum Hvpertens 1996:10(suppl 3): 157-160.
17. MacMahon S, Rodgers A: Blood pressure, antihypertensive treatment and stroke risk. J Hy-pertens 1994; 12(suppl 10):S5-S14.
18. Julius S: Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21:886-893.
19. Giannattasio C. Cattaneo BM. Mangoni AA. Carugo S, Stella ML. Trazzi S. et al: Cardiac and vascular changes in normolensive subjects with parental hypertension. J Hvpertens 1995: 13:259-264.
20. Psatv BM. Hcckbert SR. Kocpscll TD. Sisco-vick DS. Raghunathan TE, Weiss NS, et al:The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-625.
21. Pallor M, Guralnik JM, Furbcrg CD, Carbonin U. Havlik RJ: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996:347: 1061-1065.
22. Pahor M. Guralnik JM. Corti MC. Foley DJ, Carbonin PU. Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Gcriatr Soc 1995:43:1191-1197.
23. Pahor M, Guralnik JM. Salive ME. Corti MC, Carbonin P. Havlik RJ: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-699.
24. Pahor M. Guralnik JM. Ferrucci L, Corti MC, Salive MC. Cerhan JR. et al: Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996:348:493-497.
25. Mancia G, Van Zwieten PA: How safe are calcium antagonists in hypertension and coronary heart disease? J Hvpertens 1996:14:13-17.
26. Mcsserli FH: Are calcium antagonists safe? Lancet 1995;346:767-768.
27. Mcsserli FH: Case-control study, meta-analysis and bouillabaisse: Putting the calcium antagonist scare into context. Ann Intern Med 1995: 123:888-889.
28. Frolich ED, Zanchetti A: Antihypertensive therapy: Safety and efficacy of drugs and publications. J Hypertens 1996;14:273-275.
29. Mayers LC. Horwitz RJ. Feinstein AR: A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol 1986: 17:680-685.
30. Braun S. Boyko V. Bchar S, Rcicher-Rciss H. Shotan A, Schtesingcr Z, et al: Calcium antagonists and mortality in patients with coronary heart disease: A cohort study of 11.575 patients. J Am Coll Cardiol 1996:28:7-11.
31. Aursnes I, Litleskare I. Froyland H, Abdelnoor M: Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press 1995:4:157-163.
32. Jick H. Derby LE. Gurewich V. Vasilkis C:The risk of myocardial infarction in persons with uncomplicated essential hypertension associated with antihypertensive drug treatment. Pharmacotherapy 1966:16:321-326.
33. Dargie HJ. Ford I. Fox KM, on behalf of the TIBET Study Group: Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996:17: 104-112.
34. Rehnqvist N, Hjemdahl P, Billing E. Bjorkan-der I, Eriksson SV. Forslund L, et al: Effects of metoprolol versus verapamil in patients with stable angina pectoris: The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996: 17:76-81.
35. Gong L, Zhang W, Zhu Y. Zhu J. Kong D. Page V, et al: Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996:14:1237-1245.